Kenzie Maclsaac
Private Equity Investor at Cure Ventures Management LP
Profile
Dr. MacIsaac is a Partner at Cure Ventures.
Kenzie’s career spans over 13 years in drug discovery working at the cutting edge of genetics, genomics, and bioinformatics to solve pressing problems in human health.
Prior to joining Cure Ventures, Dr. MacIsaac served as a Senior Director at Bristol Myers Squibb where he built out the oncology precision medicine and bioinformatics capability at their Kendall Square discovery site, played a central role in genetically driven new target identification efforts, and made key contributions to the understanding of drug resistance, including Opdivo and Yervoy combinations.
Prior to BMS, Kenzie led Translational Bioinformatics at Fog Pharma with responsibility for their computational biology platform.
From 2014-2018 Dr. MacIsaac was a group leader at the Novartis Institutes for Biomedical Research.
While at NIBR Oncology he helped develop their strategy for using genomic data to immunophenotype cancer and drive patient selection and translational research efforts for oncology assets.
From 2009-2014 Dr. MacIsaac was a scientist at Merck Research Laboratories in their Genetics and Pharmacogenomics department, focused on the identification of genetically validated targets in immunology and respiratory disease.
Dr. MacIsaac’s academic background includes a Ph.D.
in Computer Science from the Massachusetts Institute of Technology where he studied under Dr. Ernest Fraenkel, a M.A.Sc in Electrical Engineering from the University of Toronto, and a B.Eng in Electrical Engineering from Carleton University where he graduated with highest honors.
Kenzie Maclsaac active positions
Companies | Position | Start |
---|---|---|
Cure Ventures Management LP
Cure Ventures Management LP Investment ManagersFinance Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 2022-02-28 |
Former positions of Kenzie Maclsaac
Companies | Position | End |
---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Director/Board Member | 2022-12-02 |
Fog Pharmaceuticals, Inc.
Fog Pharmaceuticals, Inc. BiotechnologyHealth Technology Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA. | Director/Board Member | 2018-11-29 |
Training of Kenzie Maclsaac
Carleton University | Undergraduate Degree |
University of Toronto | Graduate Degree |
Massachusetts Institute of Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Private companies | 2 |
---|---|
Cure Ventures Management LP
Cure Ventures Management LP Investment ManagersFinance Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts. | Finance |
Fog Pharmaceuticals, Inc.
Fog Pharmaceuticals, Inc. BiotechnologyHealth Technology Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Kenzie Maclsaac